Prostate-specific membrane antigen guided surgery.
Since its introduction in the diagnostic pathway of prostate cancer management, prostate-specific membrane antigen (PSMA)-ligand positron-emission tomography (PET) has demonstrated great potential. PSMA-ligand imaging is increasingly influencing therapeutic decision making although its impact on patient outcomes still needs to be defined. One relatively new application, enabled through chemical and engineering efforts, is PSMA guided surgery. In this review, the potential of PSMA guided surgery is highlighted and its implications on lymph node dissection in primary and recurrent prostate cancer are discussed.